Boehringer Ingelheim
Also, fellow Korean medical AI companies have obtained regulatory approvals across global markets.
Via Datavant's data utility and privacy platform, Boehringer Ingelheim can evaluate data and streamline data discovery.
The partners will leverage IBM’s foundation model technologies to help identify antibodies designed to target and neutralize various disease-causing agents or cells.
Boehringer Ingelheim and Click Therapeutics initiate clinical trial on PDTx treatment for schizophrenia and Akili's EndeavorRx shows promise for adults with ADHD.
The companies first partnered in 2020 to develop a prescription digital therapeutic for schizophrenia. They said a treatment strategy for the condition "would benefit from a multi-product approach."
This news comes roughly a year after the company signed a $500 million deal with Boehringer Ingelheim.
Yesterday, at DTx West, the pharma giant and the DTx company sat down to discuss implementing DTx for mental illness.
Also: Kaiser Permanente doubles down on the cloud with Accenture and Microsoft; Boehringer Ingelheim arms its reps with BreezoMeter's air quality data.
The companies will be collaborating on a prescription digital therapeutic for patients with schizophrenia built on Click Therapeutics' tech platform.
An updating collection of news released during this year's global health IT conference.